Compare Adobe Systems Inc (ADBE) vs Adaptive Biotechnologies Corp (ADPT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adobe Systems Inc vs Adaptive Biotechnologies Corp — how do they compare? Adobe Systems Inc trades at $220.69 (market cap $88.06B), while Adaptive Biotechnologies Corp trades at $19.98 (market cap $3.33B). The key difference: Adobe Systems Inc is far larger — about 26.4× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Adobe Systems Inc nearer its low. Which is the better fit depends on your goals.
| ADBE | ADPT | |
|---|---|---|
Market Cap | $88.06B | $3.33B |
Volume | 5,187,646 | — |
Sector | Technology | Health |
52-Week High | $382.24 | $22.37 |
52-Week Low | $193.41 | $10.24 |
Enterprise Value | $89.50B | $3.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adobe (ADBE) trades at $219.75, up 0.77% with strong fundamentals including 29.99% net margin and consistent earnings beats. The stock shows bullish technical signals despite recent volatility, with support at $218 and resistance at $228. Revenue growth accelerated to $23.77B in 2025, while institutional activity remains mixed amid AI competition concerns.
ADBE presents a compelling value opportunity with a 12.67 P/E ratio and 49% analyst buy ratings, though AI disruption fears and CEO transition create near-term uncertainty. The consensus price target of $246.75 implies 12% upside potential, balanced against sector-wide software pressures.
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adobe Systems Inc
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →
